Regeneron Pharmaceuticals Statistics
Total Valuation
REGN has a market cap or net worth of $96.50 billion. The enterprise value is $88.36 billion.
| Market Cap | 96.50B |
| Enterprise Value | 88.36B |
Important Dates
The next confirmed earnings date is Thursday, May 2, 2024, before market open.
| Earnings Date | May 2, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
REGN has 107.94 million shares outstanding. The number of shares has increased by 0.18% in one year.
| Shares Outstanding | 107.94M |
| Shares Change (YoY) | +0.18% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 2.58% |
| Owned by Institutions (%) | 89.27% |
| Float | 102.75M |
Valuation Ratios
The trailing PE ratio is 25.71 and the forward PE ratio is 19.50. REGN's PEG ratio is 1.46.
| PE Ratio | 25.71 |
| Forward PE | 19.50 |
| PS Ratio | 7.36 |
| Forward PS | 6.83 |
| PB Ratio | 3.72 |
| P/FCF Ratio | 24.90 |
| PEG Ratio | 1.46 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.83, with an EV/FCF ratio of 22.80.
| EV / Earnings | 22.35 |
| EV / Sales | 6.74 |
| EV / EBITDA | 18.83 |
| EV / EBIT | 20.68 |
| EV / FCF | 22.80 |
Financial Position
The company has a current ratio of 5.69, with a Debt / Equity ratio of 0.10.
| Current Ratio | 5.69 |
| Quick Ratio | 4.82 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.58 |
| Debt / FCF | 0.70 |
| Interest Coverage | 58.52 |
Financial Efficiency
Return on equity (ROE) is 16.10% and return on invested capital (ROIC) is 13.29%.
| Return on Equity (ROE) | 16.10% |
| Return on Assets (ROA) | 12.60% |
| Return on Capital (ROIC) | 13.29% |
| Revenue Per Employee | $975,257 |
| Profits Per Employee | $293,948 |
| Employee Count | 13,450 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 0.73 |
Taxes
In the past 12 months, REGN has paid $245.70 million in taxes.
| Income Tax | 245.70M |
| Effective Tax Rate | 5.85% |
Stock Price Statistics
The stock price has increased by +10.64% in the last 52 weeks. The beta is 0.14, so REGN's price volatility has been lower than the market average.
| Beta (1Y) | 0.14 |
| 52-Week Price Change | +10.64% |
| 50-Day Moving Average | 953.63 |
| 200-Day Moving Average | 858.33 |
| Relative Strength Index (RSI) | 27.93 |
| Average Volume (30 Days) | 473,780 |
Short Selling Information
The latest short interest is 1.42 million, so 1.32% of the outstanding shares have been sold short.
| Short Interest | 1.42M |
| Short Previous Month | 1.39M |
| Short % of Shares Out | 1.32% |
| Short % of Float | 1.38% |
| Short Ratio (days to cover) | 3.19 |
Income Statement
In the last 12 months, REGN had revenue of $13.12 billion and earned $3.95 billion in profits. Earnings per share was $34.77.
| Revenue | 13.12B |
| Gross Profit | 11.30B |
| Operating Income | 4.05B |
| Pretax Income | 4.20B |
| Net Income | 3.95B |
| EBITDA | 4.69B |
| EBIT | 4.27B |
| Earnings Per Share (EPS) | $34.77 |
Balance Sheet
The company has $10.84 billion in cash and $2.70 billion in debt, giving a net cash position of $8.14 billion or $75.43 per share.
| Cash & Cash Equivalents | 10.84B |
| Total Debt | 2.70B |
| Net Cash | 8.14B |
| Net Cash Per Share | $75.43 |
| Equity / Book Value | 25.97B |
| Book Value Per Share | 240.62 |
| Working Capital | 16.06B |
Cash Flow
In the last 12 months, operating cash flow was $4.59 billion and capital expenditures -$718.60 million, giving a free cash flow of $3.88 billion.
| Operating Cash Flow | 4.59B |
| Capital Expenditures | -718.60M |
| Free Cash Flow | 3.88B |
| FCF Per Share | $36.32 |
Margins
Gross margin is 86.16%, with operating and profit margins of 30.85% and 30.14%.
| Gross Margin | 86.16% |
| Operating Margin | 30.85% |
| Pretax Margin | 32.01% |
| Profit Margin | 30.14% |
| EBITDA Margin | 35.78% |
| EBIT Margin | 32.57% |
| FCF Margin | 29.54% |
Dividends & Yields
REGN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.18% |
| Shareholder Yield | -0.18% |
| Earnings Yield | 4.10% |
| FCF Yield | 4.02% |
Analyst Forecast
The average price target for REGN is $973.17, which is 8.86% higher than the current price. The consensus rating is "Buy".
| Price Target | $973.17 |
| Price Target Difference | 8.86% |
| Analyst Consensus | Buy |
| Analyst Count | 24 |
| Revenue Growth Forecast (5Y) | 5.59% |
| EPS Growth Forecast (5Y) | 11.40% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
REGN has an Altman Z-Score of 10.71 and a Piotroski F-Score of 6.
| Altman Z-Score | 10.71 |
| Piotroski F-Score | 6 |